Geoffrey Kline public CV

Geoffrey Kline, DO, PhD

Texas College of Osteopathic Medicine
Assistant Professor, Internal Medicine & Geriatrics

EmailGeoffrey.Kline@unthsc.edu

Source: Scopus
Calculated based on no. of publications stored in Pure and citations from Scopus

Research output per year

If you made any changes in Pure these will be visible here soon.

2 Finished
5 Active

7 results

A Readomized. Double-blind, Placebo-controlled,Parallel-group Studfy to Evaluate the Effect of SAR236553/REGN727 on the Occurrence of Cardiovascular Events in Patgients Who Have Recently Experienced an Acute Coronary Syndrome
Kline, G.
Sanofi Pasteur, Inc.
31/01/13 → 30/01/20
Project: Research
A Phase 3 Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Efficacy, Long-term Safety and Tolerability of PF-04950615 in Subjects with Primary Hyperlipidemia or Mixed Dyslipdemia at Risk of Cardiovascular Events
Kline, G.
Pfizer, Inc.
17/03/15 → 31/03/20
Project: Research
A Long-term Outcomes Study to Assess Statin Residual Risk Reduction with EpaNova High Cardiovascular Risk Patients witgh Hypertriglyceridemia (STRENGTH)
Kline, G.
Astra Zeneca
8/06/15 → 30/06/24
Project: Research
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Effects of Bempedoic Acid (ETC-I 002) on the Occurrence of Major Cardiovascular Events in Patients with, or at High Risk For,Cardiovascular Disease Who Are Statin Intolerant
Kline, G.
Esperion Therapeutics, Inc.
13/02/17 → 13/02/21
Project: Research
PROMINENT- PEMAFIBRATE TO REDUCE CARDIOVASCULAR OUTCOMES BY REDUCING TRIGLYCERIDES IN PATIENTS WITH DIABETES
Kline, G.
Kowa Research Institute, Inc.
31/03/17 → 31/03/21
Project: Research
A phase III randomised, double-blind trial to evaluate efficacy and safety of once daily empagliflozin 10 mg compared to placebo, in patients with chronic Heart Failure with reduced Ejection Fraction (HFrEF).
Kline, G.
Boehringer Ingelheim International GmbH
25/04/17 → 24/04/21
Project: Research
A phase III randomised, double-blind trial to evaluate efficacy and safety of once daily empagliflozin 10 mg compared to placebo, in patients with chronic Heart Failure with preserved Ejection Fraction (HFpEF).
Kline, G.
Boehringer Ingelheim International GmbH
25/04/17 → 24/04/21
Project: Research

Search results

A Readomized. Double-blind, Placebo-controlled,Parallel-group Studfy to Evaluate the Effect of SAR236553/REGN727 on the Occurrence of Cardiovascular Events in Patgients Who Have Recently Experienced an Acute Coronary Syndrome

A Phase 3 Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Efficacy, Long-term Safety and Tolerability of PF-04950615 in Subjects with Primary Hyperlipidemia or Mixed Dyslipdemia at Risk of Cardiovascular Events

A Long-term Outcomes Study to Assess Statin Residual Risk Reduction with EpaNova High Cardiovascular Risk Patients witgh Hypertriglyceridemia (STRENGTH)

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Effects of Bempedoic Acid (ETC-I 002) on the Occurrence of Major Cardiovascular Events in Patients with, or at High Risk For,Cardiovascular Disease Who Are Statin Intolerant

PROMINENT- PEMAFIBRATE TO REDUCE CARDIOVASCULAR OUTCOMES BY REDUCING TRIGLYCERIDES IN PATIENTS WITH DIABETES

A phase III randomised, double-blind trial to evaluate efficacy and safety of once daily empagliflozin 10 mg compared to placebo, in patients with chronic Heart Failure with reduced Ejection Fraction (HFrEF).

A phase III randomised, double-blind trial to evaluate efficacy and safety of once daily empagliflozin 10 mg compared to placebo, in patients with chronic Heart Failure with preserved Ejection Fraction (HFpEF).